CIK 0000907654
- Non-accelerated filer
- Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 363855489
- Phone
- +1 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,577,126
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,577,126. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-07 | Funicular Fund, LP See Footnote 1 | Purchase | +27,450 | $2.32 | $64K | 2,048,977 |
| 2022-04-06 | Funicular Fund, LP See Footnote 1 | Purchase | +26,806 | $2.30 | $62K | 2,021,527 |
| 2022-04-05 | Funicular Fund, LP See Footnote 1 | Purchase | +49,728 | $2.30 | $114K | 1,994,721 |
| 2022-04-04 | Funicular Fund, LP See Footnote 1 | Purchase | +122,342 | $2.26 | $276K | 1,944,993 |
| 2022-04-04 | Funicular Fund, LP See Footnote 1 | Purchase | +122,342 | $2.26 | $276K | 1,944,993 |
| 2021-12-14 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +27,500 | 27,500 | ||
| 2021-12-14 | Keuer Thomas A Chief Operating Officer | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-12-14 | Dekker C. Jeffrey Chief Financial Officer | Grant or award · Stock Option (right to buy) | +17,700 | 17,700 | ||
| 2021-12-14 | BRISTOW MICHAEL R Pres. & Chief Executive Offic | Grant or award · Stock Option (right to buy) | +95,000 | 95,000 | ||
| 2021-11-22 | Ozeroff Christopher David S.V.P., General Counsel | Purchase | +50,000 | $2.26 | $113K | 50,970 |
| 2021-05-12 | CONWAY ROBERT E Director | Purchase | +10,000 | $3.19 | $32K | 50,000 |
| 2021-05-05 | CONWAY ROBERT E Director | Purchase | +10,000 | $3.23 | $32K | 40,000 |
| 2021-01-12 | Hove Anders D Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2021-01-12 | Woosley Raymond L. Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2021-01-12 | Grais Linda Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2021-01-12 | MITCHELL DANIEL J Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2021-01-12 | CONWAY ROBERT E Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2020-12-21 | Keuer Thomas A Chief Operating Officer | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2020-12-21 | Ozeroff Christopher David S.V.P., General Counsel | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2020-12-21 | BRISTOW MICHAEL R Pres. & Chief Executive Offic | Grant or award · Stock Option (right to buy) | +190,000 | 190,000 |
Page 19 of 24 · 473 trades